AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas Journal Article
| Authors: | Elkabets, M.; Pazarentzos, E.; Juric, D.; Sheng, Q.; Pelossof, R. A.; Brook, S.; Benzaken, A. O.; Rodon, J.; Morse, N.; Yan, J. J.; Liu, M.; Das, R.; Chen, Y.; Tam, A.; Wang, H.; Liang, J.; Gurski, J. M.; Kerr, D. A.; Rosell, R.; Teixidó, C.; Huang, A.; Ghossein, R. A.; Rosen, N.; Bivona, T. G.; Scaltriti, M.; Baselga, J. |
| Article Title: | AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas |
| Abstract: | Phosphoinositide-3-kinase (PI3K)-α inhibitors have shown clinical activity in squamous cell carcinomas (SCCs) of head and neck (H&N) bearing PIK3CA mutations or amplification. Studying models of therapeutic resistance, we have observed that SCC cells that become refractory to PI3Kα inhibition maintain PI3K-independent activation of the mammalian target of rapamycin (mTOR). This persistent mTOR activation is mediated by the tyrosine kinase receptor AXL. AXL is overexpressed in resistant tumors from both laboratory models and patients treated with the PI3Kα inhibitor BYL719. AXL dimerizes with and phosphorylates epidermal growth factor receptor (EGFR), resulting in activation of phospholipase Cγ (PLCγ)-protein kinase C (PKC), which, in turn, activates mTOR. Combined treatment with PI3Kα and either EGFR, AXL, or PKC inhibitors reverts this resistance. © 2015 Elsevier Inc. |
| Keywords: | mammalia |
| Journal Title: | Cancer Cell |
| Volume: | 27 |
| Issue: | 4 |
| ISSN: | 1535-6108 |
| Publisher: | Cell Press |
| Date Published: | 2015-04-13 |
| Start Page: | 533 |
| End Page: | 546 |
| Language: | English |
| DOI: | 10.1016/j.ccell.2015.03.010 |
| PROVIDER: | scopus |
| PMCID: | PMC4398915 |
| PUBMED: | 25873175 |
| DOI/URL: | |
| Notes: | Export Date: 4 May 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work